Michel A. Duchosal

Prof. Dr. Michel A. Duchosal


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2009 in Blood
Verified
Journal Article
Open access
PDF file
ANAimable Nahimana
Aimable Nahimana
AAAntoine Attinger
Antoine Attinger
DADominique Aubry
Dominique Aubry
PGPeter Greaney
Peter Greaney
CIChristopher Ireson
Christopher Ireson
MDMichel A. Duchosal
Michel A. Duchosal
APO866 inhibits nicotinamide phosphoribosyltransferase (NMPRTase), a key enzyme involved in nicotinamide adenine dinucleotide (NAD) biosynthesis from the natural precursor nicotinamide. Intracellular NAD is essential for cell survival, and NAD depletion resulting from APO866 treatment elicits tumor cell death. Here, we determine the in vitro and in vivo sensitivities of hematologic cancer cells to APO866 using a panel of cell lines (n = 45) and primary cells (n = 32). Most cancer cells (acute myeloid leukemia [AML], acute lymphoblastic leukemia [ALL], mantle cell lymphoma [MCL], chronic lymphocytic leukemia [CLL], and T-cell lymphoma), but not normal hematopoietic progenitor cells, were sensitive to low concentrations of APO866 as measured in cytotoxicity and clonogenic assays. Treatment with APO866 decreased intracellular NAD and adenosine triphosphate (ATP) at 24 hours and 48 to72 hours, respectively. The NAD depletion led to cell death. At 96 hours, APO866-mediated cell death occurred in a caspase-independent mode, and was associated with mitochondrial dysfunction and autophagy. Further, in vivo administration of APO866 as a single agent prevented and abrogated tumor growth in animal models of human AML, lymphoblastic lymphoma, and leukemia without significant toxicity to the animals. The results support the potential of APO866 for treating hematologic malignancies.

14 April 2014 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
CBCaroline S Breton
Caroline S Breton
ANAimable Nahimana
Aimable Nahimana
DADominique Aubry
Dominique Aubry
JMJulie Macoin
Julie Macoin
PMPierre Moretti
Pierre Moretti
JBJonathan Back
Jonathan Back
CD19 is a B cell lineage specific surface receptor whose broad expression, from pro-B cells to early plasma cells, makes it an attractive target for the immunotherapy of B cell malignancies. In this study we present the generation of a novel humanized anti-CD19 monoclonal antibody (mAb), GBR 401, and investigate its therapeutic potential on human B cell malignancies.

10 July 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MGMoustafa Ghanem
Moustafa Ghanem
Irene CaffaIrene Caffa
Irene Caffa
ARAlberto Del Rio
Alberto Del Rio
JFJorge Franco
Jorge Franco
MPMarco Daniele Parenti
Marco Daniele Parenti
FPFrancesco Piacente
Francesco Piacente
Depriving cancer cells of sufficient NAD levels, mainly through interfering with their NAD-producing capacity, has been conceived as a promising anti-cancer strategy. Numerous inhibitors of the NAD-producing enzyme, nicotinamide phosphoribosyltransferase (NAMPT), have been developed over the past two decades. However, their limited anti-cancer activity in clinical trials raised the possibility that cancer cells may also exploit alternative NAD-producing enzymes. Recent studies show the relevance of nicotinic acid phosphoribosyltransferase (NAPRT), the rate-limiting enzyme of the Preiss–Handler NAD-production pathway for a large group of human cancers. We demonstrated that the NAPRT inhibitor 2-hydroxynicotinic acid (2-HNA) cooperates with the NAMPT inhibitor FK866 in killing NAPRT-proficient cancer cells that were otherwise insensitive to FK866 alone. Despite this emerging relevance of NAPRT as a potential target in cancer therapy, very few NAPRT inhibitors exist. Starting from a high-throughput virtual screening approach, we were able to identify and annotate two additional chemical scaffolds that function as NAPRT inhibitors. These compounds show comparable anti-cancer activity to 2-HNA and improved predicted aqueous solubility, in addition to demonstrating favorable drug-like profiles.

8 April 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
OEOussama ElMokh
Oussama ElMokh
SMSaki Matsumoto
Saki Matsumoto
PBPaulina Biniecka
Paulina Biniecka
ABAxel Bellotti
Axel Bellotti
KSKarin Schaeuble
Karin Schaeuble
MDMichel A. Duchosal
Michel A. Duchosal
Most cancer cells have high need for nicotinamide adenine dinucleotide (NAD+) to sustain their survival. This led to the development of inhibitors of nicotinamide (NAM) phosphoribosyltransferase (NAMPT), the rate-limiting NAD+ biosynthesis enzyme from NAM. Such inhibitors kill cancer cells in preclinical studies but failed in clinical ones. To identify parameters that could negatively affect the therapeutic efficacy of NAMPT inhibitors and propose therapeutic strategies to circumvent such failure, we performed metabolomics analyses in tumor environment and explored the effect of the interaction between microbiota and cancer cells. Here we show that tumor environment enriched in vitamin B3 (NAM) or nicotinic acid (NA) significantly lowers the anti-tumor efficacy of APO866, a prototypic NAMPT inhibitor. Additionally, bacteria (from the gut, or in the medium) can convert NAM into NA and thus fuel an alternative NAD synthesis pathway through NA. This leads to the rescue from NAD depletion, prevents reactive oxygen species production, preserves mitochondrial integrity, blunts ATP depletion, and protects cancer cells from death.Our data in an in vivo preclinical model reveal that antibiotic therapy down-modulating gut microbiota can restore the anti-cancer efficacy of APO866. Alternatively, NAphosphoribosyltransferase inhibition may restore anti-cancer activity of NAMPT inhibitors in the presence of gut microbiota and of NAM in the diet.

19 January 2009 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
ARAnne Rosselet
Anne Rosselet
DVDinh‐Hao Vu
Dinh‐Hao Vu
PMPascal Meylan
Pascal Meylan
ACAudrey S. Baur Chaubert
Audrey S. Baur Chaubert
MSMarc Schapira
Marc Schapira
MDMichel A. Duchosal
Michel A. Duchosal

21 September 2022 in European Journal of Cancer Care
Verified
Journal Article
Open access
CAChantal Arditi
Chantal Arditi
MEManuela Eicher
Manuela Eicher
SCSara Colomer-Lahiguera
Sara Colomer-Lahiguera
CBChristine Bienvenu
Christine Bienvenu
Sandro AnchisiSandro Anchisi
Sandro Anchisi
IPIsabelle Peytremann‐Bridevaux
Isabelle Peytremann‐Bridevaux
The objectives were to describe patients' experiences of cancer care in Switzerland and explore the variation of these experiences by type of cancer. The Swiss Cancer Patient Experiences (SCAPE) study was a cross‐sectional, multicentre survey conducted in 2018. Adult patients (n = 7145) with breast, prostate, lung, colorectal, skin or haematological cancer from four large hospitals in French‐speaking Switzerland were invited to complete a survey. Logistic regressions were used to assess whether experiences varied according to cancer type, adjusting for confounders. Of the 3121 persons who returned the survey (44% response rate), 2755 reporting an eligible cancer were included in the analyses. Participants' average score for overall care was 8.5 out of a maximum score of 10. Higher rates of positive experiences were found for nurse consultations (94%), diagnostic tests (85%) and inpatient care (82%). Lower positive responses were reported for support for people with cancer (70%), treatment decisions (66%), diagnosis (65%) and home care (55%). We observed non‐systematic differences in experiences of care by cancer type. This large study identified that cancer patient experiences can be improved in relation to communication, information and supportive care aspects. Improvement efforts should target these areas of care to enhance responsiveness of cancer care.